Condition: Nonalcoholic Steatohepatitis (NASH) · Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Sponsor: Corcept Therapeutics
A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
This description comes directly from the study's public registry record.
Eric Lawitz, MD · 210-253-3426 · lawitz@txliver.com
Toluwalase Okubote, MBBS, MPH, PMP · 210-253-3426 · tokubote@txliver.com
Always discuss trial participation with your own doctor first.
| Site# 433 | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07553663